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Abstract 
Long circulating liposomes entrapping iodinated and radioiodinated compounds offer a highly 
versatile theranostic platform. Here we report a new methodology for efficient and high-yield 
loading of such compounds into liposomes, enabling CT/SPECT/PET imaging and 131I-radiotherapy.  
Methods: The CT contrast agent diatrizoate was synthetically functionalized with a primary amine, 
which enabled its remote loading into PEGylated liposomes by either an ammonium sulfate- or a 
citrate-based pH transmembrane gradient. Further, the amino-diatrizoate was radiolabeled with 
either 124I (t1/2 = 4.18 days) for PET or 125I (t1/2 = 59.5 days) for SPECT, through an aromatic 
Finkelstein reaction. 
Results: Quantitative loading efficiencies (>99%) were achieved at optimized conditions. The 
124I-labeled compound was remote-loaded into liposomes, with an overall radiolabeling efficiency of 
77 ± 1%, and imaged in vivo in a CT26 murine colon cancer tumor model by PET/CT. A prolonged 
blood circulation half-life of 19.5 h was observed for the radiolabeled liposomes, whereas injections 
of the free compound were rapidly cleared. Lower accumulation was observed in the spleen, liver, 
kidney and tumor than what is usually seen for long-circulating liposomes.  
Conclusion: The lower accumulation was interpreted as release of the tracer from the liposomes 
within these organs after accumulation. These results may guide the design of systems for controlled 
release of remote loadable drugs from liposomes. 
Key words: remote loading, pH-gradient liposomes, transmembrane ammonium sulfate, iodinated imaging 
agents, I-124, PET imaging 
Introduction 
Nanoparticles and liposomes in particular, have 
been vigorously investigated due to their ability to 
improve the biodistribution of small molecular drugs. 
The multifunctional nature of liposomes has 
furthermore potentiated their use as theranostic 
agents and companion diagnostics [1]. Here, 
diagnostic liposomes are used for initial patient 
screening, while their therapeutic counterparts are 
used in follow-up treatment [2,3]. The prolonged 









of liposomes have also precipitated their use in 
imaging of the hepatic and cardiovascular systems [4], 
and for clinical and preclinical assessment of the 
enhanced permeation and retention (EPR) effect in 
tumors [5,6]. Alternative compositions such as 
nanoemulsions, micelles, polymeric and metal alloy 
nanoparticles are also being explored as reporters of 
the EPR effect [7–9]. Several imaging modalities have 
been used in combination with liposomes for 
diagnostic purposes, including gadolinium-based 
magnetic resonance imaging (MRI), 99mTc and 111In for 
single photon emission computed tomography 
(SPECT), 64Cu, 89Zr, 52Mn and 18F for positron 
emission tomography (PET) and iodine for X-ray 
computed tomography (CT) [4,5,10–19]. 
Iodine has 37 isotopes and covers most of the 
above-mentioned modalities. Non-radioactive iodine 
(127I) is radiodense and provides contrast in 
radiographic imaging agents, while various iodine 
radioisotopes are applied in molecular imaging for 
SPECT (123I, 125I and 131I) and PET (124I). Iodine 
radioisotopes are further used as radioactive tracers in 
surgical guidance [20,21], and for internal 
radiotherapy via beta irradiation (131I), photon 
irradiation (125I) and more recently in Auger therapy 
(125I) [22]. In recent years, 124I (t½ = 4.18 days) has 
gained particular attention as a long-lived 
radioisotope for PET imaging. 124I has a positron 
branch of 23% (Eaverage = 686 keV (11%) and 974 keV 
(11%)) as well as several high-energy gamma 
emissions (511 keV (46%), 603 keV (61%), 723 keV 
(10%) and 1691 keV (11%) [23]. Recent phase I/II 
studies have demonstrated 124I to be a valuable 
theranostic agent supporting current clinical 131I 
treatments of differentiated thyroid cancer, by 
improving staging, grading and lesion delineation 
using PET imaging [24]. Taking advantage of the 
well-established iodine radiochemistry, labeling 
procedures can easily be adapted for each 
radioisotope. This gives access to either SPECT, PET 
or CT modalities for imaging and low-energy beta 
particle therapy [25]. The combination of iodine and 
liposomes thus offers a highly versatile theranostic 
platform. 
 Visualization of the blood pool and tumor 
vasculature has previously been investigated using 
liposomes labeled with iodine or radioiodine through 
either: i) passive encapsulation, ii) membrane 
incorporation of chemically modified iodo-lipids, or 
iii) remote-loading of iodine-rich species [4,26,27]. 
Passive encapsulation, however, suffers from low 
encapsulation efficiencies and laborious preparation 
procedures [28–31], while remote loading of 
liposomes using the well-known Bolton-Hunter 
reagent offers iodine loading efficiencies of only about 
60% [32]. Accordingly, there is an unmet need to 
develop new methods for loading iodinated 
compounds into liposomes with quantitative loading 
efficiencies.  
Transmembrane chemical potentials across lipid 
bilayers created by ion gradients can be used as a 
driving force for loading compounds into liposomes 
with high efficiency, as previously demonstrated for 
the clinically approved formulation DoxilTM [33–36]. 
In recent studies, similar approaches were applied to 
load radionuclides, such as the single photon emitter 
99mTc, the therapeutic radioisotope 186Re and positron 
emitters 64Cu and 52Mn [10,13,17,37–39]. 
In the present study, we report a new method for 
loading liposomes with an iodine-rich compound 
(Figure 1). Diatrizoic acid, an iodinated CT contrast 
agent used clinically for visualization of, e.g., the 
bowel [40] and in digital subtraction angiography 
[41], was functionalized to carry a primary amine, 
enabling its remote loading into liposomes by a 
transmembrane pH gradient. While the unprotonated 
species may traverse the lipid membrane, protonation 
inside the liposome serves to trap it there. Remote 
loading was accomplished using either citrate- or 
ammonium sulfate-based pH gradients, and was 
further optimized by varying the pH of the utilized 
buffers, the compound-to-lipid ratio, and the duration 
of the loading procedure. 124I radioiodinated diatrizoic 
acid analogues were obtained by an aromatic 
Finkelstein reaction [42], and were remote loaded into 
stealth liposomes. The biodistribution of the 
124I-radiolabeled stealth liposomes and the free 
compound was evaluated by PET/CT imaging and ex 
vivo gamma counting in tumor-bearing mice. 
Radiolabeling of liposomes with 125I via remote 
loading was furthermore conducted as part of the 
optimization procedure.  
Such iodine-loaded liposomal theranostic agents 
are highly valuable for future biomedical 
applications, including diagnosis and staging of 
disease and for evaluation of therapeutic responses. 
Methods 
Materials 
For synthesis of the imaging agent, starting 
materials, reagents and solvents were purchased from 
commercial suppliers and used without further 
purification. All solvents beside 2-methoxy-ethanol 
were HPLC grade and dry solvents were obtained via 
an Innovative Technology PS-MD-7 puresolv system. 
[124I]NaI and [125I]NaI were purchased from 
PerkinElmer Life Science as solutions in aqueous 
NaOH (0.02 M and 10-5 M, respectively). 






Figure 1. Remote loading of the amino diatrizoic acid (ADA) imaging agent (A) into liposomes by transmembrane pH gradients. Possible iodine labels for SPECT, 
therapy, PET and CT are outlined. Equilibria governing the remote loading of amine-functionalized compounds into liposomes via ammonium sulfate-based (B) or 
citrate-based (C) pH gradients are shown. 
 
The lipid mixture, composed of hydrogenated 
soy L-α-phosphatidylcholine (HSPC), cholesterol 
(CHOL) and 1,2-distearoyl-sn-glycero-3-phosphoe-
thanolamine-N-[methoxy(polyethylene glycol)-2000] 
(ammonium salt) (DSPE-PEG2000) in the molar ratio 
HSPC:CHOL:DSPE-PEG2000 (56.5:38.2:5.3), was 
purchased from Lipoid GmbH. 1,2-dipalmitoyl- 
sn-glycero-3-phosphoethanolamine-N (lissamine 
rhodamine B sulfonyl) (ammonium salt) (Rho-DPPE) 
was purchased from Avanti Polar Lipids. Reagents 
used in the ICP-MS experiments, nitric acid and 
tetramethylammonium hydroxide solution (25% in 
H2O), were TraceSelect® and purchased from Fluka 
Analytical and Te, Ga, P standards and potassium 
iodide were purchased from Sigma-Aldrich. 
Ammonium sulfate, citric acid, trisodium citrate 
dihydrate, sodium phosphate monobasic dihydrate, 
sodium phosphate dibasic dihydrate, sodium 
chloride, sodium carbonate, HEPES ([4-(2- 
hydroxyethyl)-piperazino]-1-ethanosulfonic acid) and 
HEPES sodium salt, Trizma®base (tris(hydroxyme-
thyl)aminomethane), MES (2-(N-morpholino) 
ethanesulfonic acid), and CHES (2-(cyclo-
hexylamino)ethanesulfonic acid), were purchased 
from Sigma-Aldrich. Water used for all experiments 
was collected from a Milli-Q system (Millipore). 
Illustra™ MicroSpin™ G-50 columns and PD-10 
desalting columns were from GE Healthcare. 
Slide-A-Lyzer® 10k Dialysis Cassettes were from 
ThermoScientific. Amicon® Ultra (4 and 0.5 mL; 30k 
and 100k) centrifugal filter devices were purchased 
from Millipore. Sep-Pak® Plus Silica cartridges (690 
mg sorbent per cartridge, 55-105 µm particle size) 
were purchased from Waters. TLC plates (Silica gel 60 
F254) were purchased from Merck. 
An isotonic HEPES buffer (25 mM HEPES, 150 
mM NaCl) was prepared by mixing HEPES and 
HEPES sodium salt in Milli-Q water and adjusted to 
pH 7.4 with HCl (osmolality: 310 mOsm/kg). 
Phosphate buffer was prepared by mixing sodium 
phosphate monobasic dihydrate and sodium 
phosphate dibasic dihydrate to obtain pH 7.0 (25 mM 
phosphate, 150 mM NaCl, pH 7.0, 326 mOsm/kg). 
CHES buffer (25 mM CHES, 150 mM NaCl, pH 9.0, 
310 mOsm/kg), MES buffer (25 mM MES, 150 mM 
NaCl, pH 6.0, 307 mOsm/kg) and TRIS buffer (25 mM 
TRIS, 150 mM NaCl, pH 8.0, 313 mOsm/kg) were 
prepared in Milli-Q water and the pH values were 
adjusted with HCl/NaOH to desired pH. Sodium 
citrate buffer was prepared by mixing citric acid and 
trisodium citrate dihydrate for the final pH of 4.0 (200 
mM citrate, pH 4.0, 380 mOsm/kg). 
Synthesis of amino diatrizoic acid (ADA)  
Diatrizoic acid 1 was esterified by nucleophilic 
substitution of 2-(boc-amino)ethyl bromide (1.5 
equiv.) in DMF at 50 °C by forming the corresponding 
carboxylate of 1 using K2CO3 (1.2 equiv). This 
afforded the ester 2 in fair yield (48%). The Boc-group 
of 2 was subsequently removed using TFA in CH2Cl2 
yielding the TFA salt of 3 in quantitative yield (For 
detailed synthetic procedures and NMR spectra of 
final product, see Supporting Information data S1). 
Compound 3 is hereafter referred to as amino 
diatrizoic acid (ADA). 






Scheme 1. Synthetic scheme of amino-functionalized diatrizoic acid (3) and radioiodination. 
 
Synthesis of [124I]ADA and [125I]ADA 
[124I]ADA and [125I]ADA were synthesized using 
an aromatic Finkelstein reaction (iodine-iodine 
exchange) modified from Aissi et al [42]. Amino 
diatrizoic acid (ADA) (0.35 mg, 0.45 µmol, TFA salt) 
was dissolved in glacial acetic acid (240 µL) in a glass 
vial, followed by adding a dispersion of CuSO4 in 
glacial acetic acid (120 µL, 1.0 mg/mL, 0.76 µmol). 
[124I]NaI as an aqueous solution in 0.02 M NaOH (120 
µL, 109 MBq) was added and the mixture was 
magnetically stirred in a closed vial at 130 °C for 2.5 h. 
After cooling to ambient temperature, ethyl acetate 
(720 µL) was added to the mixture and the resulting 
solution was applied to a Sep-Pak Plus Silica 
cartridge. The product was subsequently isolated by 
sequential elution of 10 fractions (F) according to the 
following scheme: F1: neat ethyl acetate (3 mL), F2: 
EtOH:EtOAc:AcOH (75:25:1) (2 mL), F3: 
EtOH:EtOAc:AcOH (90:10:1) (1 mL), F4: EtOH:EtOAc 
(90:10) (1 mL), F5: EtOH:25% aq. NH4OH (99:1) (1 
mL), F6: EtOH:25% aq. NH4OH (98:2) (1 mL), F7: 
EtOH:25% aq. NH4OH (97:3) (1 mL), F8: EtOH:25% 
aq. NH4OH (96:4) (1 mL), F9: EtOH:25% aq. NH4OH 
(95:5) (1 mL), F10: EtOH:25% aq. NH4OH (95:5) (1 
mL). Fractions 5-10 were pooled and evaporated to 
dryness at 70 °C under a stream of air for 35 min, 
furnishing the desired product. Likewise, to 
radiolabel ADA with 125I, ADA (1.0 mg, 1.3 µmol, TFA 
salt) was dissolved in glacial acetic acid (100 µL) and a 
dispersion of CuSO4 in glacial acetic acid was added 
(100 µL, 1.0 mg/mL, 0.63 µmol). An aqueous solution 
of [125I]NaI in 10-5 M NaOH (3 µL, 8.7 MBq) and water 
(7 µL) was added to this mixture. The resulting 
solution was magnetically stirred at 130 °C for 30 min. 
After cooling to room temperature, ethyl acetate (400 
µL) was added to the mixture. The product was 
isolated using a Sep-Pak Plus Silica cartridge and 
sequential elution in accordance with the above 
gradient scheme. Fractions F5-10 were evaporated to 
dryness at 60 °C under a stream of air for 45 min. 
Preparation of liposomes with a 
transmembrane ammonium gradient  
The lipid mixture composed of 
HSPC:CHOL:DSPE-PEG2000 (56.5:38.2:5.3 molar ratio) 
was mixed with Rho-DPPE in a tert-butanol:water 
(9:1) (0.2 mol% fluorescent lipid), and lyophilized 
overnight. Rhodamine B was included for UV-VIS 
detection of these liposomes. The freeze-dried lipid 
was hydrated in 150 mM ammonium sulfate (pH 5.3, 
330 mOsm/kg) for 1 h at 65 °C and seven freeze-thaw 
cycles were conducted before sizing to large 
unilamellar vesicles (LUVs). To form LUVs, the 
liposome suspension was extruded through either 200 
nm or 100 nm (for the in vivo PET study) pore sized 
polycarbonate membranes by an Avanti mini 
extruder at 65 °C. The hydrodynamic diameter and 
size distribution of the liposomes were determined by 
dynamic light scattering (ZetaSizer, Malvern 





Instruments) and the phosphorous content by ICP-MS 
(iCAP Q, Thermo Scientific).  
The ammonium sulfate gradient was created 
using Slide-A-Lyzer® 10K Dialysis Cassettes (buffer 
volume was 300-fold the volume of the sample) for 
buffer exchange with buffers having different pH 
values. The dialysis buffer was replaced three times 
with new buffer to provide a successful buffer 
exchange. The external buffers were isotonic 25 mM 
phosphate buffer pH 7.0, TRIS pH 8.0, CHES pH 9.0 or 
MES pH 6.0 buffers all containing 150 mM NaCl. The 
average hydrodynamic diameter of the liposomes was 
146 nm (PDI: 0.062). 
Preparation of liposomes with a citrate based 
transmembrane pH gradient  
Large unilamellar vesicles (LUVs) were prepared 
as previously described using a 200 mM sodium 
citrate buffer (C6H8O7: Na3C6H5O7, pH 4.0, 380 
mOsm/kg) for hydration. The liposome solution was 
incubated for 1 h at 65 °C, followed by seven 
freeze-thaw cycles. The transmembrane pH gradient 
was formed by increasing the external pH of 
liposomes to a desired pH of 7.0 by adding aq. sodium 
carbonate (1 M, pH 11.8), resulting in a final lipid 
concentration of 50 mM (volume ratio of base and 
liposomes Vbase/Vliposome = 0.2). The hydrodynamic 
diameters of the liposomes extruded through 200 nm 
or 100 nm filters were 142 nm (PDI = 0.072) or 137 
(PDI = 0.042) respectively. 
Remote loading and quantification of ADA and 
[124I]ADA  
Having formed the ion gradient across the 
liposome membrane, the liposome dispersion was 
added to solid ADA. As an example, 2.2 mg ADA (2.9 
µmol) was mixed with aq. 550 uL liposomes (50 mM 
lipid). For the ammonium sulfate gradient liposomes, 
a fixed ADA-to-lipid molar ratio of 0.1 was used for 
the method optimization in combination with varying 
the external pH (6-9) and incubation time (1-24 h). For 
the citrate gradient liposomes, ADA-to-lipid ratios 
from 0.1 to 1.0 were investigated at constant lipid 
concentration and as a function of the incubation time 
(1-24 h). Initial screening revealed 55 °C to be the 
optimal incubation temperature when judged by 
loading rate (data not shown). All samples were 
heated and continuously stirred at 55 °C.  
Quantification of the liposome loading 
efficiency of ADA 
The loading efficiency was quantified as the ratio 
of the ADA-to-lipid ratio before and after 
microcolumn separation of the free and liposome 
entrapped ADA. Briefly, a 25 μL liposome sample was 
applied to the Illustra MicroSpin G-50 columns (GE 
Healthcare) and centrifuged at 2000 ×g for 4 min. The 
ADA-to-lipid ratio (before and after column 
separation) was determined by UV-VIS spectroscopy 
(NanoDrop 2000C, ThermoScientific), where 
rhodamine labeled DPPE acted as a surrogate for the 
full lipid sample. Samples with ADA-to-lipid ratio of 
0.1, 0.25, 0.5 or 1.0 were diluted either 150, 300, 600 or 
1200-fold in ethanol containing 0.6 v/v % TFA 
respectively, prior to the UV-VIS measurement in 
order to dissolve the liposomes and assure 
protonation of ADA. The absorbance of ADA and 
Rho-DPPE (liposomes) were measured at 243 nm 
(λmax) and 560 nm (λmax) respectively, and the loading 
efficiency was calculated as (Equation 1):  
 % 𝐿𝐿𝐿𝐿 = 𝐴𝐴243,𝑎𝑎
𝐴𝐴560,𝑎𝑎 ⋅  𝐴𝐴560,𝑏𝑏𝐴𝐴243,𝑏𝑏 ∙ 100% 
where A243,b and A243,a denote the peak absorbance of 
ADA before and after column separation respectively. 
A560,b and A560,a denote the peak absorbance of 
Rho-DPPE (liposome) before and after column 
separation respectively (Figure S3 and Figure S4).  
Iodine and phosphor concentrations of the 
liposomes were in addition quantified by ICP-MS 
(Thermo Scientific, iCAP Q) to verify the loading 
efficiency determined by UV-VIS spectroscopy 
(Figure S5).  
Preparation of [124I]ADA in HEPES buffer for 
in vivo study 
Radiolabeled [124I]ADA (45.3 MBq, 1.2 µmol) was 
dissolved in EtOH:H2O (7:1, 800 µL). From this 
solution, 110 µL (5.24 MBq) was evaporated to 
dryness under argon flow for 5 min at 70 °C. The 
residue was redissolved in isotonic HEPES buffer (500 
µL) and used directly for the in vivo study. The final 
activity concentration was 9.0 MBq/mL at the time of 
injection. 
Preparation of [124I]ADA loaded liposomes for 
in vivo study 
Citrate-based transmembrane pH gradient 
liposomes for the in vivo study were prepared as 
described above, resulting in liposomes with 
hydrodynamic diameters of 137 nm (PDI = 0.04). 
Radiolabeled [124I]ADA (45.3 MBq, 1.2 µmol) was 
dissolved in EtOH:H2O (7:1, 800 µL), whereafter 39 
MBq (690 uL) was transferred to an HPLC vial and 
evaporated to dryness under argon flow for 5 min at 
70 °C. Citrate-based transmembrane pH gradient 
liposomes (50 mM, 510 µL) were added to the dry 
[124I]ADA (39 MBq) and incubated for 3 h at 55 °C 
with continuous stirring. The initial ADA-to-lipid 





molar ratio was 0.04. After loading, non-encapsulated 
[124I]ADA and external citrate buffer were removed by 
exchanging the external medium with HEPES buffer 
(25 mM, 150 mM NaCl, pH 7.4, 310 mOsm/kg) using 
PD-10 desalting columns (GE Healthcare). The final 
lipid and activity concentration of the collected 
liposomes were 10.2 mM and 20.5 MBq/mL at the 
time of injection.  
Quantification of the [124I]ADA loading 
efficiency 
[124I]ADA-loaded liposomes and free [124I]ADA 
were separated using PD-10 desalting columns (GE 
Healthcare). The sample was applied to the column 
and 500 µL fractions were collected by eluting with 
isotonic HEPES buffer. The radioactivity of the 
collected fractions was measured using a dose 
calibrator (CRC-55tR, Capintec, Inc.). The loading 
efficiency was calculated as the ratio of the 
radioactivity of 124I in the liposome fraction to the total 
radioactivity in the collected fractions. Furthermore, 
the PD-10-purified 124I-liposomes were analyzed by 
thin-layer chromatography (TLC) in order to 
determine the radiochemical purity. 2 µL of purified 
[124I]ADA-liposomes were spotted on a TLC plate 
(Silica gel 60 F254) and ethanol:25% aq. NH4OH (99:1) 
was used as eluent. The radio-TLC was measured 
using a phosphor imager (Cyclone Plus, PerkinElmer) 
and the [124I]ADA compound was identified at Rf = 
0.35, which was identical to the non-radioactive 
reference (ADA).  
Cryo-TEM imaging 
3 µL of liposome solution was placed on a lacy 
carbon 300 mesh copper TEM grid, blotted and 
plunge frozen in liquid ethane using a FEI Vitrobot 
Mark IV. Samples were imaged using a FEI Tecnai G2 
20 TWIN transmission electron microscope operated 
at 200 keV in low-dose mode with a FEI 
High-Sensitive (HS) 4k × 4k Eagle camera. 
 Animal model 
Tumors were established by subcutaneous 
injection of 3×105 CT26 murine colon cancer cells 
(CRL-2638, American Type Culture Collection, ATCC, 
VA, USA) suspended in 100 μL of culture medium 
over the thigh/flank of 7-week-old female BALB/c 
mice (Janvier Labs, France). Cells were grown in vitro 
in culture flasks using RPMI medium (Gibco, Thermo 
Fisher, Waltham, Massachusetts, USA) supplemented 
with bovine serum albumin (Gibco, Thermo Fisher, 
Waltham, Massachusetts, USA) and Penicillin 
Streptomycin (Pen Strep, (Gibco, Thermo Fisher, 
Waltham, Massachusetts, USA)) before inoculation in 
mice. Cells were tested for murine virus, human virus, 
mycoplasma, and lastly tested for cell line 
authentication to exclude cross-contamination during 
in vitro growth. Tumors were allowed to grow for 16 
days before study start. The National Animal 
Experiments Inspectorate approved all study 
procedures (license no. 2016-15-0201-00920). 
MicroPET/CT imaging procedure  
PET/CT imaging was performed on an Inveon® 
small animal PET/CT system (Siemens Medical 
Systems, PA, USA). Mice were anesthetized by 
inhalation of anesthesia (~3% sevoflurane) and either 
3.46 ± 0.04 MBq/mouse of [124I]ADA -liposomes (n = 
5) or 1.39 ± 0.05 MBq/mouse of [124I]ADA in HEPES (n 
= 3) was injected into the tail vein. The mice receiving 
liposomes were each administered 1.3 mg lipid and 71 
µg ADA, whereas the mice administered the free 
compound received 29 µg ADA each. Decay-corrected 
injected activities were determined by gamma 
counting syringes before and after injections. 
[124I]ADA -liposomes or [124I]ADA was allowed to 
distribute for 18 min before commencing a 5 min PET 
scan (Scan1) and a corresponding CT scan. Additional 
PET/CT scans were performed after a distribution 
period of 1.5 h (Scan2) (5-min acquisition), 20 h 
(Scan3) (10-min acquisition), 48 h (Scan4) (15-min 
acquisition) and 70 h (Scan5) (15-min acquisition). 
Emission data were corrected for dead time and decay 
and attenuation correction was performed based on 
the corresponding CT scan. PET scans were 
reconstructed using a maximum a posteriori (MAP) 
reconstruction algorithm (0.815×0.815×0.796 mm). 
Image analysis was performed using Inveon® 
software (Siemens Medical Systems, PA, USA). 3D 
regions of interest (ROIs) were manually constructed 
and decay-corrected data (%injected dose per gram 
tissue (%ID/g)) are reported.  
Gamma counting 
For post mortem analysis, the following tissues 
were collected and transferred into pre-weighed 
gamma counter tubes: blood, liver, spleen, kidney, 
tumor and thyroid gland (complete larynx region). All 
tubes were well counted using an 124I setup and decay 
corrected (Wizard gamma counter, Perkin Elmer, 
Waltham, MA. USA). The specific activity is reported 
as %ID/g and is based on the total injected activity 
and the measured activity and weight of the tissue 
samples. The activity of the thyroid gland was 
determined from the overall activity in the excised 
complete larynx region, which was not further 
dissected to avoid damaging the thyroid. The 
measured activity was assumed to be primarily from 
the thyroid gland and activity is therefore reported as 
injected dose in the thyroid gland (%ID/thyroid). 





Results and Discussion 
Synthesis and characterization of ADA  
A diatrizoic acid derivative (ADA) was 
synthesized by esterification with 2-(boc-amino)ethyl 
bromide. This introduced an amino group to enable 
remote loading into liposomes via a transmembrane 
pH gradient. The pKa value of the primary amine on 
ADA was determined to be 8.56 ± 0.04 (n = 4) by 
acid-base titration and LogD values of -0.6 (pH 5) and 
0.6 (pH 7.4) were estimated using the ChemAxon 
software package (Figure S1 and Figure S2). The pKa 
and corresponding change in hydrophilicity upon 
protonation of the amine allows ADA to traverse lipid 
membranes at neutral pH but not at lower pH values. 





Optimizing the remote loading of ADA into 
liposomes  
Remote loading of ADA into stealth liposomes 
was conducted using either an ammonium sulfate- or 
a citrate-based pH gradient method. A Rho-DPPE 
lipid fluorophore was included to enable 
quantification of the lipid fraction. The loading 
efficiency could therefore be determined by UV-VIS 
spectrophotometry (Figure 2A), via the absorbance of 
ADA at 243 nm and Rho-DPPE at 560 nm. By use of 
Equation 1, the loading efficiency, %LE, was 
determined via the ADA-to-lipid ratio before and 
after removal of non-loaded ADA by spin column 
separation (see Figure S3 and Figure S4 for UV-VIS 
spectra of ADA and liposomes used for quantification 
of the loading efficiencies). Iodine and phosphor 
concentrations of several UV-VIS samples were in 
addition quantified by ICP-MS for verification of the 
method (Figure S5). For both sets of liposomes, dry 
ADA solids were stirred directly with the liposomes, 
 
 
Figure 2. Remote loading of non-radioactive ADA into liposomes via transmembrane ammonium sulfate or citrate pH gradients. (A) UV-VIS spectra of 
ADA-loaded liposomes before and after removal of free ADA by MicroSpin column separation. Inset: normalized UV-VIS spectra where the absorbance of 
Rho-DPPE at 560 nm has been set to unity. The normalized spectrum enables direct comparison of the ADA-to-lipid ratio before and after removal of non-loaded 
ADA by spin column separation. (B) The loading efficiency of ADA into ammonium sulfate gradient liposomes is shown as a function of time and external pH. The 
loading experiments were conducted at a 0.1 ADA-to-lipid molar ratio and at 55 °C. (C) The loading efficiency of ADA into citrate gradient liposomes is shown 
as a function of the ADA-to-lipid ratio and time. The loading experiments were conducted at 55 °C with an external pH of 7.0. (D) Cryo-TEM images of 
ADA-loaded ammonium sulfate liposomes with an ADA-to-lipid ratio of 0.2. (E) Cryo-TEM images of ADA-loaded sodium citrate liposomes with an ADA-to-lipid 
ratio of 0.2. The scale bars are 100 nm. 





and all reported loading efficiencies describe the 
combined process of initial dissolution and 
subsequent loading of ADA into the liposomes. Both 
solubility and membrane permeation are highly 
dependent on the overall charge of ADA and thereby 
dependent of the pH outside the liposomes. An 
optimal pH of 7.0 was identified for the ammonium 
sulfate gradient liposomes (at 55 °C and 0.1 
ADA-to-lipid ratio), yielding a maximal loading 
efficiency of 86 ± 2% after 6 h of stirring, followed by a 
12% decline in the loading efficiency at 24 h (Figure 
2B). Liposomes with an external pH of 6.0 exhibited 
the lowest loading efficiencies, reaching a maximal 
loading of 27 ± 1% after 24 h of stirring (Figure 2B). 
The reduced loading efficiency at pH 6.0 is likely 
caused by poor membrane permeation of the 
protonated ADA species leading to slow loading 
kinetics. At external pH 8.0 and 9.0, the maximal 
loading efficiency was reached at 2 h, yielding 56 ± 1% 
and 78 ± 3% respectively (Figure 2B). The reduction in 
loading efficiency obtained at pH 8.0 and 9.0 
compared to pH 7 may be explained by lower 
solubility and/or slow dissolution kinetics of the dry 
ADA at higher external pH values due to limited 
protonation. Further studies are required to 
determine the exact cause of the reduced loading 
efficiency found at pH 6, 8 and 9 compared to pH 7.  
Having identified an optimal external pH of 7.0, 
citrate gradient-based liposomes were investigated. 
These liposomes were prepared in citrate buffers with 
an internal lumen pH of 4.0, and an external pH of 7.0. 
This procedure utilizes the polyprotic nature of 
citrate, and provides an instant pH gradient across the 
liposome membranes in a quick and simple manner. 
Using this method, concentrated liposome samples 
(50 mM lipid) were prepared with membrane 
gradients of ∆pH = 3.0, without any purification steps 
and with limited sample dilution (~20% upon 
addition of sodium carbonate). Such liposomes of 
high lipid concentration and simple gradient 
formation are highly warranted when large 
compound payloads are desired. In order to 
determine the maximal payload of ADA into the 
citrate-based liposomes, the loading efficiency was 
determined for the ADA-to-lipid molar ratios 0.1, 
0.25, 0.5 and 1.0. For all ADA-to-lipid molar ratios, the 
loading efficiency remained approximately constant 
at the 1, 2, 3 and 6 h time-points, beyond which a 
slight decrease in loading efficiency was observed for 
the 0.1 ADA-to-lipid ratio (Figure 2C). This decrease 
in loading efficiency after 12-24 h incubation may be 
governed by slow dissipation of the citrate pH 
gradient, resulting in unloading of the ADA 
compound. Similar observations have been reported 
by Forster et al [43]. Loading efficiency levels of 98 ± 
1%, 90 ± 2%, 73 ± 3% and 38 ± 2% were obtained at 
ADA-to-lipid ratios of 0.1, 0.25, 0.5 and 1.0 
respectively, demonstrating that the citrate pH 
gradient is gradually exhausted as more ADA 
compound is loaded into the core of the liposomes. 
This observation is in accordance with previous 
reports [44]. The effectively entrapped payload of 
ADA per liposome, given as the product of the 
loading efficiency and the ADA-to-lipid molar ratio, 
increases from [ADA]/[Lipid] = 0.098, 0.23, 0.37 to 
0.38 for ADA-to-lipid molar ratios 0.1, 0.25, 0.5 and 1.0 
respectively. The effective entrapped payload thus 
converges towards [ADA]/[Lipid] = 0.38, which 
corresponds to 14.5 mg iodine/mL for a 100 mM lipid 
solution. Hence, production of long-circulating high 
CT contrast liposomes by remote loading using the 
current approach seems to not be feasible, as 50-200 
mg/mL iodine is often required to obtain significant 
CT contrast levels [4,31]. Improved payloads of iodine 
in liposomes may still be obtained by entrapping 
higher citrate concentrations and/or utilizing 
liposomes with increased diameter. However, such 
changes impact the osmotic transmembrane gradient 
and systemic circulation properties of the liposome 
[45]. Cryo-TEM images of citrate and ammonium 
sulfate gradient liposomes loaded with ADA are 
shown in Figure 2D-E, displaying populations of 
spherical monodisperse liposomes in both cases. 
Neither the citrate- nor ammonium sulfate-based 
liposomes were found to entrap visible precipitates of 
ADA at an ADA-to-lipid ratio of 0.2, such as is found 
in Doxil where crystals of doxorubicin are present 
after remote loading [46,47].  
Radiolabeling of ADA with 124I and 125I 
124I substitution of iodine on ADA was 
conducted using a modified Cu(I)-catalyzed 
nucleophilic isotopic exchange reaction (Scheme 1) 
[42]. The radiochemical purity of the purified 
[124I]ADA was >90%, with a radiochemical yield of 
34-55% and a specific activity of 83 MBq/µmol. ADA 
was in addition radiolabeled with 125I through a 30 
min reaction, which resulted in a radiochemical purity 
of 94% and a higher purified radiochemical yield of 
64%. Since 124I could only be acquired in lower 
concentration than 125I, it was necessary to conduct the 
radiolabeling with this radionuclide at higher water 
concentrations. This was observed to drastically lower 
the reaction rate, which made it necessary to extend 
the reaction time. This led to an increased presence of 
impurities and lowered radiochemical yields for the 
124I radiolabeling. Radiochemical conversion (not 
purified) for similar reaction conditions on an 
ortho-iodinated benzyl group has previously been 
reported to be around 75-82% after 30 min of reaction, 





with a slight drop to around 70% after 45 min [42]. 
Accordingly, our RCYs and conversion for 125I are on 
par with reported values and the extended reaction 
time may compromise yields, likely due to harsh 
reaction conditions. The reaction used is theoretically 
applicable to all isotopes of iodine, but as was 
observed, the concentration and manner in which an 
isotope can be acquired may affect practical 
procedures. 
Remote loading of [124I]ADA and [125I]ADA 
into liposomes  
For remote loading of the radiolabeled analogue 
of ADA, liposomes entrapping citrate were chosen 
due to their higher loading efficiency and faster 
loading kinetics (Figure 2B-C) when compared to 
their ammonium sulfate counterparts. The 
longer-lived [125I]ADA analogue was used for the 
initial optimization of the radio-TLC and PD-10 size 
exclusion column analyses, as well as for the test 
loading of liposomes. Subsequently, the [124I]ADA 
analogue was synthesized for evaluation of the 
liposome biodistribution in mice by PET/CT imaging 
and organ well counting. The average radiochemical 
purity of [125I]ADA and [124I]ADA was 93.0 ± 0.6% (n = 
4) when assessed by radio-TLC (Figure S6). However, 
remote loading of both [125I]ADA and [124I]ADA, with 
subsequent size exclusion purification, resulted in 
radiochemical purities of more than 99% (Figure 3B) 
in all cases. We believe this to be a result of only the 
target compound (ADA) undergoing remote loading, 
whereas other small-molecular radioactive impurities 
were removed by the PD-10 purification. The average 
loading efficiency was 77 ± 1% (n = 4) when assessed 
by PD-10 column separation (Figure 3A). Overall, this 
correspond to 84% of the loadable activity being 
entrapped in the liposomes, which is a 30% 
improvement compared to the Bolton-Hunter reagent 
method reported by Mougin-Degraef et al [32]. 
For the in vivo studies, the liposome sample was 
purified on a PD-10 column, with concomitant 
exchange of the medium from hypertonic citrate (380 
mOsm/kg) to isotonic HEPES buffer. After column 
separation, citrate gradient liposomes were collected 
with lipid and radioactivity concentrations of 10.2 
mM and 20.5 MBq/mL respectively at the time of 
injection. The loading efficiency after column 
purification was 98%. The stability of the 
encapsulation of the loaded radiotracer was assessed 
by incubating the [124I]ADA liposomes at 25 °C for 168 
h in HEPES buffer. This resulted in an encapsulation 
efficiency of 98 ± 1% (n = 3), testifying to the excellent 
stability of this loading method. 
In vivo evaluation of [124I]ADA loaded 
liposomes 
[124I]ADA and [124I]ADA liposomes were well 
tolerated by all mice and no reactions to the injections 
or during the observation period were seen. 
Representative MIP and axial PET/CT images are 
shown in Figure 4 (see Figure S8 for sagittal and 
coronal PET/CT images). Biodistributions of free and 
liposome-loaded [124I]ADA in CT26 tumor-bearing 
mice at each time-point were determined from the 
PET scans (Figure 5A-E). The biodistributions were 
further verified by gamma counting organs including 




Figure 3. Characterization of [124I]ADA loaded liposomes by size exclusion column separation and radio-TLC. (A) Elution profile of [124I]ADA-loaded liposomes by 
PD-10 column separation. The liposomes were eluted with 25 mM HEPES buffer (150 mM NaCl, pH 7.4, 310 mOsm/kg), with a loading efficiency of 77.2%. (B) 
Radio-TLC peak of [124I]ADA after loading into liposomes. 
 






Figure 4. MIP and axial PET/CT images of systemically administered free [124I]ADA and [124I]ADA-loaded liposomes in CT26 tumor-bearing mice at 15 min, 90 min 
20 h, 48 h and 70 h pi. The position of the axial image projections is illustrated for the 70 h timepoint using yellow dotted lines.  
 
 For free [124I]ADA, rapid blood clearance (Figure 
5A) and urinary excretion during the first 15 min were 
observed (Figure 5E). Rapid clearance of free 
[124I]ADA from the spleen, liver and kidney, and low 
tumor activity was also observed (Figure 5B-C), 
reflecting the rapid clearance of free [124I]ADA from 
the blood pool within these organs. [124I]ADA thus 
exhibits the typical renal clearance of small, polar 
substances. After 72 h, a total retention of 0.015 %ID 
was determined in the thyroid by well counting 
(Figure 5F). Assuming a thyroid weight of 11 mg [48], 
this corresponds to 1.4 %ID/g accumulation in the 
thyroid of the non-liposomal [124I]ADA. This is likely 
to be a result of the bulk of the radioactivity clearing 
from the organism before appreciable deiodination of 
[124I]ADA has occurred. The limited thyroid 
accumulation indicates that the compound is 
relatively stable in vivo. In comparison, administration 
of free 131I- in rats resulted in 270 %ID/g accumulation 
in the thyroid after 6 h [49]. 
Contrary to the free compound, 
[124I]ADA-loaded liposomes circulated with a half-life 
of 19.7 h, when estimated by a mono-exponential fit of 
data collected during 0-72 h (R2 = 0.98). At the first 
PET scan (t = 15 min), 29.3 %ID/g, 12.0 %ID/g and 
10.8 %ID/g were found in the blood, liver and spleen 
respectively, accounting for approximately 74% of the 
total activity when assuming organ/blood weight 
percentages (%w/w) of 8.5%, 4.9% and 0.54% for 
blood, liver and spleen [50] and a 23 g average body 
weight of the BALB/c mice. The circulating half-life of 
the [124I]ADA-loaded liposomes is comparable to 
earlier reports for liposomal CT contrast agents [27] 
and for liposomes carrying 64Cu- and 
52Mn-radiolabels that are known to be stable in vivo 
[5,11,15,17,51]. This, as well as the minimal 
radioactivity in the urinary bladder, which could be 
either in the form of [124I]ADA or breakdown 
products, (Figure 5E) substantiate that the stealth 
liposomes entrapping [124I]ADA are stable during 
circulation in the blood. Liver, spleen and kidneys 
also displayed the expected activity of liposomal 
[124I]ADA, which corresponds with previous reports 
on comparable nanoparticles. The highest activity was 
observed at 1.5 h post injection (pi.) for these organs, 
which contradicts earlier reports on long-circulating 
liposomes where the maximal accumulation typically 
occurred after 12-40 h [10,17]. This indicates that 
radioactivity was able to leave these organs during 
the imaging period, which is not expected to occur if 
[124I]ADA is maintained within the stealth liposome. 
The tumor-to-blood ratio, shown in Figure 5D, 
increases as a function of time for the liposomal 
[124I]ADA, further indicating that the extravascular 
activity in this region increases with respect to the 
intravascular as a result of EPR-dependent liposome 





accumulation. Previous biodistribution studies of 
stealth liposomes have proven these to be very stable 
in circulation [5,17,51], which suggests that free 
[124I]ADA or breakdown products were released from 
the liposomes after accumulation. The absence of a 
precipitate in the cryo-TEM images (Figure 2D-E) 
lends support to this hypothesis, as formation of 
crystalized [124I]ADA inside the liposomes would 
have been likely to slow down the release kinetics 
[52]. This release may be a result of uptake and 
digestion of the liposomes by resident immune cells, 
or loss of the trans-membrane pH-gradient. The latter 
possibility was previously suggested as a reason for 
unloading of liposomal doxorubicin [53]. In vitro 
studies by Forster et al. and Mayer et al. showed that 
the pH gradient of liposomes composed of EPC or 
DPPC may dissipate over time when incubated at 37 
°C in buffer or serum, which supports our hypothesis 
that [124I]ADA may have leaked from the liposomes 
after they had accumulated [43,54]. Since higher 
thyroid accumulation was observed for the liposomal 
[124I]ADA (1.06 %ID/thyroid, 96 %ID/g assuming a 
thyroid weight of 11 mg [48], Figure 5F) compared to 
freely administered [124I]ADA, the compound is 
probably released from the organs of uptake, with 
subsequent renal excretion and only limited 
deiodination, as thyroid entrapment of free iodine 
would have been more pronounced. In comparison, 
Ke and coworkers reported a 12-fold higher thyroid 
accumulation (12.9 %ID/thyroid) for euthyroid mice 
upon administration of 131I [55]. 
The stability of [*I]ADA was further investigated 
in vitro to shed light on the possible deiodination of 
the compound (Figure S7). In this test assay, the 
radiolabeled compound was incubated at 37 °C with 
mouse serum (50%), mouse liver homogenate in PBS 
and neat PBS as control, and the mixtures were 
monitored by radio-TLC for 3 days. Liver homogenate 
was included as a test for deiodination, due to the 
high presence of deiodinases in this organ. No 
breakdown was observed in PBS, whereas about 5% 
[*I]ADA was degraded after 3 days in serum and 
about 10% in the liver homogenate. Multiple 
metabolites were observed, suggesting that other 
pathways of degradation besides deiodination took 
place. That degradation was slightly more 
pronounced in the liver homogenate may be a result 
of deiodination occurring. In general, however, the 
compound exhibited good stability in both biological 
samples, which is also supported by the relatively 




Figure 5. PET-derived biodistribution of free [124I]ADA and [124I]ADA loaded liposomes. (A-E) The accumulation of free [124I]ADA (n = 3) and [124I]ADA-loaded 
liposomes (n = 5) in (A) blood, (B) liver, kidney and spleen, (C) tumor, and (D) tumor-to-blood ratio are shown as a function of time post injection (pi.). The 
radioactivity in the urinary bladder (E) was measured 15 min post injection. The results are presented as mean ± SEM for all organs and blood, whereas the tumor is 
given as both mean ± SEM and max ± SEM. (F-G) Ex vivo biodistribution data, 72 h post injection, of free [124I]ADA (n = 3) and [124I]ADA-loaded liposomes (n = 5), 
based on organ well counting. The data are presented as mean ± SEM. The thyroid uptake is expressed as %ID ± SEM per thyroid. 





The low short-term degradation and 
deiodination of the [*I]ADA compound observed in 
vitro further supports the low thyroid accumulation 
observed for [124I]ADA administered in HEPES. The 
longer blood circulation, higher liver accumulation, 
and the more pronounced in vitro degradation of 
[124I]ADA incubated in liver homogenate also 
supports the 70-fold higher thyroid accumulation for 
the liposomal [124I]ADA compared to free [124I]ADA 
(Figure 5F). Partially lipophilic drugs, like [124I]ADA, 
are expected to be taken up in hepatocytes and 
possibly undergo enzymatic modifications, which 
may explain the higher thyroid accumulation for the 
liposomal [124I]ADA. Liposomes are, on the other 
hand, expected to be taken up in the liver by resident 
Kupffer cells. Further studies are needed to decipher 
the histological distribution of [124I]ADA and its 
consequences for release and deiodination. The mean 
tumor accumulation of 1.5 %ID/g (Figure 5C) is 
likewise lower than the 4-6 %ID/g normally reported 
for CT26 tumor-bearing mice after accumulation for 
24 h [17], which suggests that 124I leaves the tumor in 
an undetermined form. The potential indication of a 
continuous release of 124I in some chemical form, 
possibly [124I]ADA, could bias our calculated half-life 
for [124I]ADA-liposomes in circulation. Considering 
the high blood radioactivity observed, this is only of 
minor concern following the observed rapid urinary 
excretion of [124I]ADA when administered in its free 
form.  
The procedure for radiolabeling liposomes with 
radioiodine presented here involves an early 
radiolabeling step, giving a radiolabeled small 
molecule that is subsequently purified and loaded 
into liposomes. This mirrors previous procedures, 
such as the use of the Bolton-Hunter reagent [32] as 
well as the use of radiolabeled prosthetic groups. For 
a clinically used radiopharmaceutical this is a 
disadvantage due to the increased handling of 
radioactive material. This could potentially be limited 
by automation. In the case at hand, this could involve 
the initial radiolabeling happening in a vessel 
containing CuSO4 and the substrate, to which AcOH 
and the radioiodine could be added, followed by 
heating. Automated Sep-Pak purification would 
benefit from a fixed aq. NH4OH concentration in the 
eluting medium, which is likely to be possible. To the 
dried compound, the liposome dispersion would 
simply be added and heated to effectuate loading. To 
avoid size exclusion chromatography, an improved 
Sep-Pak purification step would be beneficial to 
reduce radioactive impurities to below 5%. As the 
loading itself is quantitative, this would likely give a 
sufficiently radiochemically pure product. 
Despite the potential concern of using 
[124I]ADA-liposomes as imaging agents to determine 
the maximum accumulation levels of liposomes in 
tumors and their biodistribution over extended 
periods, the observations in the present study are 
highly encouraging towards developing liposomes 
for therapeutic use. The prolonged retention in and 
slow release of drugs from liposomes is a potential 
Achilles heel for liposomal delivery of anti-cancer 
drugs. The [124I]ADA-liposomes display a continuous 
relatively stable activity level in tumors and this 
indicates that their content of [124I]ADA is 
continuously released at a rate high enough to 
equilibrate their EPR-dependent accumulation. New 
classes of anti-cancer therapeutics or pro-drugs, etc. 
constructed with chemical characteristics comparable 
to [124I]ADA may therefore prove beneficial to avoid 
slow release kinetics and become directly available to 
cells within the tumors.  
Conclusion  
We introduced a versatile technique to formulate 
radioiodine in liposomes in quantitative 
encapsulation yields. This was achieved by 
radioiodination of a membrane-crossing compound, 
[124I]ADA, that was remote loaded by an ion gradient. 
The loaded radioiodinated species was found to be 
stably encapsulated in circulation, as well as in vitro. 
In vivo, however, evidence of release of the 
radioiodine was observed after uptake in organs such 
as liver and spleen as well as tumor. This observation 
is highly encouraging for the future development and 
construction of liposomal anti-cancer drugs, as drugs 
with compatible chemical characteristics as ADA may 
provide means to overcome the problematic 
entrapment stability of liposomes and subsequent 
slow release kinetics of chemotherapeutics.  
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